论文部分内容阅读
为明确荧光原位杂交在检测膀胱癌患者尿液，膀胱冲洗液中脱落细胞间期核染色体数目畸变的临床应用价值，收集２２例膀胱癌患者的尿液，２１例膀胱冲洗液，分别做尿细胞学、流式细胞术及荧光原位杂交的检测。同时收集５例正常人，５例前列腺增生患者尿液及２例膀胱冲洗液标本作为对照。结果显示：膀胱癌患者尿液组中尿细胞学、流式细胞术、荧光原位杂交分析阳性率分别为２７．３％（６／２２），４５．５％（１０／２２）和５０．０％（１１／２２），三者联合阳性率达６８．２％。膀胱冲洗液中阳性率则分别为２０．０％（４／２０），４０．０％（８／２０），７１．４％（１５／２１）和７６．２％（１６／２１）。认为荧光原位杂交技术检测膀胱癌患者尿液、冲洗液脱落细胞染色体畸变，可作为膀胱癌诊断的一项重要方法，并可能在术后监测复发以及预后判断中具有重要的临床意义。
In order to clarify the clinical value of fluorescence in situ hybridization in the detection of urine and bladder transitional cell chromosome aberrations in bladder cancer patients, we collected 22 cases of bladder cancer patients urine and 21 cases of bladder irrigation fluid, respectively, urine Cytology, flow cytometry and fluorescence in situ hybridization detection. At the same time, 5 cases of normal people, 5 cases of benign prostatic hyperplasia patients urine and 2 cases of bladder irrigation fluid specimens as a control. The results showed that the positive rates of urinary cytology, flow cytometry and fluorescence in situ hybridization in urinary bladder cancer patients were 27.3% (6/22), 45.5% (10/22) and 50% respectively. 0% (11/22), the combined positive rate of the three reached 68.2%. The positive rates of bladder irrigation were 20.0% (4/20), 40.0% (8/20), 71.4% (15/21) and 76.2% (16/21), respectively. It is considered that fluorescent in situ hybridization (FISH) can detect the chromosomal aberration of exfoliated cells in urine of bladder cancer patients as an important method for diagnosis of bladder cancer and may have important clinical significance in monitoring postoperative recurrence and prognosis.